Anixa Biosciences Presents Breast Cancer Vaccine Phase 1 Data Showing All Major Endpoints Met

PUBT · 3d ago
Anixa Biosciences Presents Breast Cancer Vaccine Phase 1 Data Showing All Major Endpoints Met
  • Anixa Biosciences completed its Phase 1 breast cancer vaccine trial, meeting all major endpoints; Phase 2 enrollment is the next milestone.
  • Among 35 patients dosed, 74% showed the protocol-specified immune response; no safety concerns were reported.
  • Combining the vaccine with Keytruda produced no additional adverse effects, supporting combination use.
  • Lira-cel remains in Phase 1 development for ovarian cancer, with periodic data releases tied to enrollment.
  • Cash and short-term investments totaled $14 million as of July 31, 2026, with no debt; last fiscal year's cash burn was $7 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.